• LAST PRICE
    0.7649
  • TODAY'S CHANGE (%)
    Trending Up0.0149 (1.9867%)
  • Bid / Lots
    0.7100/ 2
  • Ask / Lots
    0.7800/ 1
  • Open / Previous Close
    0.7875 / 0.7500
  • Day Range
    Low 0.7300
    High 0.7900
  • 52 Week Range
    Low 0.5000
    High 4.2600
  • Volume
    1,607
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.75
TimeVolumeABVC
09:32 ET3170.7875
10:36 ET1000.73
01:02 ET3090.73
01:44 ET1000.7649
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesABVC
ABVC Biopharma Inc
25.0M
-1.1x
---
United StatesCMMB
Chemomab Therapeutics Ltd
25.4M
-0.1x
---
United StatesAPRE
Aprea Therapeutics Inc
25.4M
-0.1x
---
United StatesPLUR
Pluri Inc
26.6M
-0.7x
---
United StatesTRVN
Trevena Inc
26.4M
-0.4x
---
United StatesNYMX
Nymox Pharmaceutical Corp
25.9M
-3.1x
---
As of 2022-12-04

Company Information

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development of drugs and medical devices, all of which are derived from plants. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.

Contact Information

Headquarters
44370 Old Warm Springs BlvdFREMONT, CA, United States 94538-6148
Phone
510-668-0881
Fax
---

Executives

Chairman of the Board, Chief Business Officer
Eugene Jiang
Chief Executive Officer
Howard Doong
Chief Financial Officer
Leeds Chow
Chief Scientific Officer
Chi-Hsin King
Director
Chang-Jen Jiang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$25.0M
Revenue (TTM)
$343.0K
Shares Outstanding
32.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.31
EPS
$-0.69
Book Value
$0.31
P/E Ratio
-1.1x
Price/Sales (TTM)
72.8
Price/Cash Flow (TTM)
---
Operating Margin
-5,372.76%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.